April 16, 2020

The Immunotherapy Series, Part Three: Policy and the FDA

The Immunotherapy Series, Part Three: Policy and the FDA

Immunotherapy and Policy. How can the FDA evolve to help advance and support novel approaches to medicine? How does the field of immune-driven diagnostics serve as a case in point for the need for evolution in existing regulatory frameworks?




Special guests:

Meghan Gutierrez

Chief Executive Officer

Lymphoma Research Foundation




Leo David Wang, M.D., Ph.D.

Assistant Professor, Department of Immuno-Oncology

Assistant Professor, Department of Pediatrics

City Of Hope




This series is brought to you ad-free by Adaptive Biotechnologies

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Apple Podcasts podcast player iconSpotify podcast player iconYouTube podcast player iconPodcast Addict podcast player iconCastbox podcast player iconPocketCasts podcast player iconiHeartRadio podcast player iconRSS Feed podcast player icon
Apple Podcasts podcast player iconSpotify podcast player iconYouTube podcast player iconPodcast Addict podcast player iconCastbox podcast player iconPocketCasts podcast player iconiHeartRadio podcast player iconRSS Feed podcast player icon

Immunotherapy and Policy. How can the FDA evolve to help advance and support novel approaches to medicine? How does the field of immune-driven diagnostics serve as a case in point for the need for evolution in existing regulatory frameworks?


Special guests:

Meghan Gutierrez

Chief Executive Officer

Lymphoma Research Foundation


Leo David Wang, M.D., Ph.D.

Assistant Professor, Department of Immuno-Oncology

Assistant Professor, Department of Pediatrics

City Of Hope


This series is brought to you ad-free by Adaptive Biotechnologies

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.